U.S. markets close in 4 hours 5 minutes
  • S&P 500

    4,160.56
    +25.62 (+0.62%)
     
  • Dow 30

    34,013.53
    +192.23 (+0.57%)
     
  • Nasdaq

    13,888.23
    +101.96 (+0.74%)
     
  • Russell 2000

    2,213.24
    +25.03 (+1.14%)
     
  • Crude Oil

    61.88
    -0.79 (-1.26%)
     
  • Gold

    1,793.80
    +15.40 (+0.87%)
     
  • Silver

    26.52
    +0.68 (+2.65%)
     
  • EUR/USD

    1.2038
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.5750
    +0.0130 (+0.83%)
     
  • GBP/USD

    1.3938
    +0.0001 (+0.01%)
     
  • USD/JPY

    108.1000
    +0.0300 (+0.03%)
     
  • BTC-USD

    56,066.02
    +518.64 (+0.93%)
     
  • CMC Crypto 200

    1,292.52
    +29.56 (+2.34%)
     
  • FTSE 100

    6,895.29
    +35.42 (+0.52%)
     
  • Nikkei 225

    28,508.55
    -591.83 (-2.03%)
     

Growing evidence on Oxford shot should guide other countries, vaccine chief says

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, March 2 (Reuters) - Real-world data on the effectiveness of Oxford and AstraZeneca's COVID-19 vaccine in older people from its rollout in Britain should help inform decision making in other countries, Oxford Vaccine Group Director Andrew Pollard said on Tuesday.

Asked if other countries should look at real world data from Public Health England, Pollard said: "I think that the scientific committees in each of these countries will be doing exactly that over the days ahead.

"The strength of evidence that we're now seeing... all of that is being accessed by scientific committees in different countries, and I'm sure will help support their decision making," he told BBC radio. (Reporting by Alistair Smout; editing by Michael Holden)